Thomas Ernst, PD Dr. med.
Thomas Ernst, PD Dr. med.
There is currently no available treatment, capable to increase the rate of sustained deep molecular remissions after TKI discontinuation in CML. Venetoclax could be such a drug. The study will provide unprecedented biological insights on the effects of venetoclax in controlling minimal residual stem cell disease induced by long-term prior TKI therapy. If the study would be positive, the findings could become practice changing for patients in deep molecular remission under TKI and willing to tolerate a temporary additional treatment.
Chronic Myeloid Leukemia
Venetoclax
Phase 2
Study Type : | Interventional |
Estimated Enrollment : | 10 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | Venetoclax After TKI to Target Persisting Stem Cells in CML |
Actual Study Start Date : | August 31, 2023 |
Estimated Primary Completion Date : | December 1, 2025 |
Estimated Study Completion Date : | December 1, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Venetoclax Venetoclax will be taken orally once daily (400 mg) for 12 months after stop of TKI |
Drug: Venetoclax |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
RWTH Aachen University Hospital
Aachen, Germany, 52074
Recruiting
Jena University Hospital
Jena, Germany, 07747